Dupilumab Versus Mepolizumab for COPD: Evaluating Efficacy Outcomes Using Placebo-Adjusted Indirect Treatment Comparison
This ITC suggests potential clinical benefits of dupilumab over mepolizumab in reducing exacerbations and improving lung function, respiratory symptoms, and quality of life in patients with COPD and type 2 inflammation. Direct head-to-head trials are necessary to confirm these results and better guide treatment choices.
Authors
- Nick Freemantle (ORCID: https://orcid.org/0000-0001-5807-5740)
- Surya Prakash Bhatt (ORCID: https://orcid.org/0000-0002-8418-4497)
- Yann Cabon
- Mena Soliman (ORCID: https://orcid.org/0000-0003-4066-1535)
- Jigna Heble
- Yingxin Xu
- Ernesto Mayen Herrera
- Joe Yang
Institutions
- Regeneron (United States) (US)
- Morristown Medical Center (US)
- University of Alabama at Birmingham (US)
- MRC Clinical Trials Unit at UCL (GB)
- CIEP (FR)
- C3I (United States) (US)
- University College London (GB)
Publication Details
- Journal
- Pulmonary Therapy
- Published
- 2025-09-26
- DOI
- https://doi.org/10.1007/s41030-025-00322-1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00